PER® International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

Transformative clinical trials of PARP inhibitors have revolutionized the frontline treatment paradigm in advanced ovarian cancer.

Strategies with PARP inhibitors in ovarian cancer should focus on combination strategies to more effectively treat a heterogeneous patient population.

The surge of treatment options for patients with ovarian cancer poses a daunting challenge as answers for optimal sequencing continue to elude clinicians.

Robert L. Coleman, MD, FACOG, FACS, discusses recent advancements made in the cervical cancer space.

Brian M. Slomovitz, MD, discusses sequencing strategies in endometrial cancer.